Nova Mentis Life Science (Nova Mentis Life Science) Total Current Assets : $0.02 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Nova Mentis Life Science's total current assets for the quarter that ended in Mar. 2024 was $0.02 Mil.

Nova Mentis Life Science Total Current Assets Historical Data

The historical data trend for Nova Mentis Life Science's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Total Current Assets Chart

Nova Mentis Life Science Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

1.61

0.67

2.02

0.26

0.21

Nova Mentis Life Science Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Mar24
Total Current Assets	Get a 7-Day Free Trial															0.36	0.21	0.16	0.03	0.02

Nova Mentis Life Science Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Nova Mentis Life Science's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.197	+	0.006	+	0	+	0.005
	=	0.21

Nova Mentis Life Science's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.016	+	0.005	+	0	+	0
	=	0.02

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Nova Mentis Life Science (OTCPK:NMLSF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Nova Mentis Life Science's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.016	-	0.735	+	0.75 * 0.005	+	0.5 * 0
=	-0.72

Nova Mentis Life Science Total Current Assets Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

HN3Q:Germany NOVA:Canada

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.